JP2011521969A - 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 - Google Patents

眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Download PDF

Info

Publication number
JP2011521969A
JP2011521969A JP2011511843A JP2011511843A JP2011521969A JP 2011521969 A JP2011521969 A JP 2011521969A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011511843 A JP2011511843 A JP 2011511843A JP 2011521969 A JP2011521969 A JP 2011521969A
Authority
JP
Japan
Prior art keywords
composition
kinase
inhibitor
activin receptor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011511843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521969A5 (enExample
Inventor
中村，弘
ユエ，ベアトリス，ワイ．，ジェイ．，ティー．
Original Assignee
スムマ ヘルス システムズ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スムマ ヘルス システムズ エルエルシー filed Critical スムマ ヘルス システムズ エルエルシー
Publication of JP2011521969A publication Critical patent/JP2011521969A/ja
Publication of JP2011521969A5 publication Critical patent/JP2011521969A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011511843A 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件 Pending JP2011521969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5746108P 2008-05-30 2008-05-30
US61/057,461 2008-05-30
PCT/US2009/045607 WO2009146408A1 (en) 2008-05-30 2009-05-29 Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions

Publications (2)

Publication Number Publication Date
JP2011521969A true JP2011521969A (ja) 2011-07-28
JP2011521969A5 JP2011521969A5 (enExample) 2011-09-08

Family

ID=41377599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511843A Pending JP2011521969A (ja) 2008-05-30 2009-05-29 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件

Country Status (5)

Country Link
US (1) US20100087486A1 (enExample)
EP (1) EP2285380A4 (enExample)
JP (1) JP2011521969A (enExample)
CN (1) CN102083439A (enExample)
WO (1) WO2009146408A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695511A (zh) * 2009-04-17 2012-09-26 舒玛健康系统有限责任公司 抑制眼部瘢痕形成的转化生长因子-β受体抑制剂的用途
BR112013003600A2 (pt) * 2010-08-17 2016-08-16 Allergan Inc agonistas ep2 ou ep4 para o tratamento de névoa da córnea
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
JP6429280B2 (ja) 2013-05-14 2018-11-28 国立大学法人京都大学 効率的な心筋細胞の誘導方法
RU2016106641A (ru) 2013-07-30 2017-09-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтические средства, направленные на ecm эндотелия роговицы
EP3031905A4 (en) 2013-08-07 2017-04-26 Kyoto University Method for producing pancreatic hormone-producing cell
AU2014316100B2 (en) 2013-09-05 2020-11-05 Eisai R&D Management Co., Ltd. New method for inducing dopamine-producing neural precursor cells
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
EP3147353B1 (en) 2014-05-21 2022-03-30 Kyoto University Method for producing pancreatic blast cells and pancreatic disease treatment agent containing pancreatic blast cells
EP3380121B1 (en) * 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
JP7011260B2 (ja) 2016-04-22 2022-02-10 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
CN106282092A (zh) * 2016-09-07 2017-01-04 山东省眼科研究所 一种角膜内皮分离和扩增培养液
EP3633026A4 (en) 2017-05-25 2021-03-10 Kyoto University METHOD FOR INDUCING THE DIFFERENTIATION OF A MESODERMAL INTERMEDIATE CELL TO A KIDNEY PRECURSOR CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF A PLURIPOTENT STEM CELL FROM A KIDNEY PRECURSOR CELL
US20200405768A1 (en) 2018-02-19 2020-12-31 Sumitomo Dainippon Pharma Co., Ltd. Cell Aggregate, Mixture of Cell Aggregates, and Method for Preparing Same
JP7357369B2 (ja) 2018-07-23 2023-10-06 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
EP3970795A4 (en) 2019-05-15 2023-06-14 Ajinomoto Co., Inc. Method for purifying neural crest cells or corneal epithelial cells
JPWO2020235319A1 (enExample) 2019-05-20 2020-11-26
CN114375328B (zh) 2019-09-06 2024-12-27 学校法人庆应义塾 包含胶质前体细胞的细胞聚集体的制备方法
EP4043553A4 (en) 2019-10-01 2023-11-22 Kyoto University METHOD FOR ISOLATING URETERAL NODLE CELLS
BR112022018640A2 (pt) 2020-03-19 2022-11-08 Orizuru Therapeutics Inc Métodos para produzir uma população de células compreendendo cardiomiócitos e para purificar cardiomiócitos, população de células contendo cardiomiócitos, e, agente para terapia de transplante de células
EP4123016A4 (en) 2020-03-19 2024-06-19 Orizuru Therapeutics, Inc. Method for purifying cardiomyocytes
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
US20240010989A1 (en) 2021-01-08 2024-01-11 Kyoto University Medium for culturing and expanding nephron progenitor cells, method for culturing and expanding nephron progenitor cells, and method for producing renal organoids
EP4353243A4 (en) 2021-06-10 2025-06-25 Ajinomoto Co., Inc. METHOD FOR PRODUCING MESENCHYMAL STEM CELLS
JPWO2022265086A1 (enExample) 2021-06-17 2022-12-22
WO2023286852A1 (ja) 2021-07-15 2023-01-19 株式会社セルファイバ 構造体及びその用途
EP4386083A4 (en) 2021-08-11 2025-11-12 Univ Kyoto METHOD FOR PRODUCING RENAL INTERSTITIAL PROGENITOR CELLS, ERYTHROPOIETIN-PRODUCING CELLS AND METHOD FOR PRODUCING RENIIN-PRODUCING CELLS
US20250163385A1 (en) 2022-02-01 2025-05-22 Kyoto University Method for producing lung mesenchymal cells and lung mesenchymal cells
CN118679244A (zh) 2022-02-09 2024-09-20 住友制药株式会社 判定培养液中的细胞在由多能干细胞向中脑底板区域的神经系统细胞的分化中的分化能力的方法
EP4530344A1 (en) 2022-05-23 2025-04-02 Kyoto University Production method for renal collecting duct cells and pelvic epithelial cells
US20260097083A1 (en) 2022-09-26 2026-04-09 Kyoto University Method for producing pancreatic endoderm cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527590A (ja) * 2002-04-04 2005-09-15 バイオジェン， インコーポレイテッド 三置換ヘテロアリールおよびそれらを製造し使用する方法
JP2007533734A (ja) * 2004-04-21 2007-11-22 アイエヌ２ジェン カンパニー リミテッド Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類
WO2008006583A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
WO1995009003A1 (en) * 1993-09-29 1995-04-06 Alcon Laboratories, Inc. Compositions containing growth factors and antimetabolites
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
CA2149657A1 (en) * 1993-09-29 1995-04-06 Billie M. York Compositions containing growth factors and antiplastic agents
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US6063396A (en) * 1994-10-26 2000-05-16 Houston Biotechnology Incorporated Methods and compositions for the modulation of cell proliferation and wound healing
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AU2002357003A1 (en) * 2001-12-28 2003-07-24 Guilford Pharmaceuticals Inc. Indoles as naaladase inhibitors
AU2003300099A1 (en) * 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
DE602004014347D1 (de) * 2003-03-12 2008-07-24 Millennium Pharm Inc Chinazolin-derivate als tgf-beta-inhibitoren
ES2389258T3 (es) * 2003-06-17 2012-10-24 Millennium Pharmaceuticals, Inc. Composiciones y métodos para inhibir TGF-s
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) * 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US20060234911A1 (en) * 2005-03-24 2006-10-19 Hoffmann F M Method of reversing epithelial mesenchymal transition
CN101330914A (zh) * 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
US7524640B2 (en) * 2006-08-06 2009-04-28 Children's Medical Center Corporation Inhibiting Smad2/3 signaling promotes neurite outgrowth in dorsal root ganglia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527590A (ja) * 2002-04-04 2005-09-15 バイオジェン， インコーポレイテッド 三置換ヘテロアリールおよびそれらを製造し使用する方法
JP2007533734A (ja) * 2004-04-21 2007-11-22 アイエヌ２ジェン カンパニー リミテッド Ａｌｋ５及び／又はａｌｋ４の抑制剤としての２−ピリジル置換イミダゾール類
WO2008006583A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013041065; Ｌｉｕ　Ｘｉｎｇ-Ｊｕｎ　ｅｔ　ａｌ．: Ｂｉｏｔｅｃｈｎｏｌｏｇｙ　ｌｅｔｔｅｒｓ Ｖｏｌ．２７，　Ｎｏ．２０, 2005, ｐ．１６０９-１５ *
JPN6013041067; Ｔｏｊｏ，Ｍ．　ｅｔ　ａｌ．: Ｃａｎｃｅｒ　ｓｃｉｅｎｃｅ Ｖｏｌ．９６，　Ｎｏ．１１, 2005, ｐ．７９１-８００ *
JPN6013041069; 雑賀司珠也: 臨床眼科 Ｖｏｌ．６１，　Ｎｏ．２, 2007, ｐ．１５６-１６３ *
JPN6013041072; 新田信一: あたらしい眼科 Ｖｏｌ．１８，　Ｎｏ．１, 2001, ｐ．３-７ *
JPN6013041074; 高橋保志: 医薬ジャーナル Ｖｏｌ．３４，　増刊号, 1998, ｐ．２３７-２４２ *

Also Published As

Publication number Publication date
US20100087486A1 (en) 2010-04-08
EP2285380A1 (en) 2011-02-23
WO2009146408A9 (en) 2010-12-02
WO2009146408A1 (en) 2009-12-03
EP2285380A4 (en) 2012-03-14
CN102083439A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
JP2011521969A (ja) 眼疾患を治療するためのＴＧＦ−β受容体阻害剤又はアクチビン様キナーゼ（ＡＬＫ）５阻害剤、Ａ−８３−０１及びＳＢ−４３１５４２の使用方法及び創傷治療条件
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
JP2012524073A (ja) 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
Morales et al. Intraoperative mitomycin and corneal endothelium after photorefractive keratectomy
JP7730816B2 (ja) 過剰血管新生に関連する眼疾患を治療する化合物
JP2019518790A (ja) 緑内障手術の成功率を向上させるためにニンテダニブを使用する組成物および方法
TWI720582B (zh) ＶＥＧＦ和ＴＧＦβ的多激酶抑制劑及其用途
CN109996814B (zh) 多激酶抑制剂及在眼部纤维化中的用途
CN105050600B (zh) 眼底疾病治疗剂
JPH02501483A (ja) 緑内症または高眼圧症治療剤
KR20010040457A (ko) 안약 조성물
JP2016514123A (ja) ジピリダモールを用いる眼疾患の治療において使用するための組成物
JP6861634B2 (ja) 眼疾患を処置するための組成物及び方法
Ianchulev Suprachoroidal space as a therapeutic target
WO2007050720A1 (en) Loteprednol etabonate against vascular dysfunction in the eye
JPH08503968A (ja) 増殖因子と代謝拮抗物質を含有する組成物
TW201717958A (zh) 眼壓下降增強劑
Gillies et al. Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy
WO2019117813A1 (en) Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
Wang et al. AGTR1 blocker attenuates activation of Tenon's capsule fibroblasts after glaucoma filtration surgery via the NF-κB signaling pathway
WO2022164996A1 (en) Methods of treating ocular fibrotic pathologies
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物
JP7429500B2 (ja) 角膜上皮障害治療剤
KR102068697B1 (ko) 염증성 안구표면질환의 예방 또는 치료용 조성물
Dubey et al. Management of neovascular glaucoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140212